Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead, ViiV, NMAC, HRC, NBJC, GLAAD and others offer $5.5 million in grants to help community groups respond to monkeypox.
Generic cabotegravir, an every-other-month injectable to prevent HIV, will arrive in select countries. WHO and Health Gap have opinions.
Cultural influencers promote HIV prevention.
Cultural influencers take off their blindfolds to destigmatize HIV prevention in ViiV’s “Me in You, You in Me” campaign. [VIDEOS]
Drugmaker Gilead Sciences led in private HIV/AIDS funding, reports FCAA, noting “a dangerous reliance on a shrinking pool of funders.”
ViiV Healthcare’s Risk to Reasons initiative offers stigma-free language for discussing HIV and Black women. Apply now for grants.
The Women as the Face of AIDS Summit, organized by Iris House, also honored three trailblazing women working to end the HIV epidemic.
How UNAIDS, PEPFAR, WHO and other global AIDS groups are racing to get HIV meds to Ukrainians who need them to survive.
AIDS United spearheads the rebranded Harm Reduction Futures Fund to also prevent HIV, viral hepatitis and overdoses.
The approval makes this the first single-pill regimen containing dolutegravir available in a water-dispersible formulation.
Funded by ViiV Healthcare, the National AIDS Memorial’s award honors AIDS activist and poet Mary Bowman, who died at age 30.
The Food and Drug Administration approved Apretude as the first long-acting injectable option for pre-exposure prophylaxis.
Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.
The grants to groups across nine Southern states are funded in part by Gilead Sciences COMPASS Initiative to End HIV in the South. [VIDEO]
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.